A prediction model for breast cancer recurrence after adjuvant hormone therapy

International Journal of Biological Markers

Volumn 23, Issue 4, 2008, Pages 199-206

  Boracchi, P ^a   Coradini, D ^b   Antolini, L ^b   Oriana, S ^c   Dittadi, R ^d   Gion, M ^d   Daidone, M G ^b   Biganzoli, Elia ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Casa di Cura Ambrosiana   (Italy)

^d OSPEDALE DEGLI INFERMI   (Italy)

Author keywords

Adjuvant tamoxifen; Breast cancer; Nomogram; Relapse prediction

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SIZE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENERAL HOSPITAL; GENOMICS; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREDICTION; PROGNOSIS; PROTEOMICS; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; METABOLISM; MIDDLE AGED; NOMOGRAM; PATHOLOGY; PREDICTION AND FORECASTING; STATISTICAL MODEL; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 65349171945     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2009.457     Document Type: Article

References (36)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67.
2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn H-J. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-65.
3. Coradini D, Oriana S, Biganzoli E, et al. Relationship between steroid receptors (as continuous variables) and response to adjuvant treatments in postmenopausal women with node-positive breast cancer. Int J Biol Markers 1999; 14: 60-7.
4. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-27.
5. Biganzoli E, Boracchi P, Daidone MG, Gion M, Marubini E. Flexible modelling in survival analysis. Structuring biological complexity from the information provided by markers. Int J Biol Markers 1998; 13: 107-23.
6. Coradini D, Daidone MG, Boracchi P, et al. Time-dependent relevance of steroid receptors in breast cancer. J Clin Oncol 2000; 18: 2702-9.
7. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000; 19: 453-73.
8. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130: 515-24.
9. Harrell FE Jr. Predicting outcomes: applied survival analysis and logistic regression. Charlottesville: University of Virginia Press, 1998.
10. Revision of the standards for the assessment of hormone receptors in human breast cancer: Report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer 1980; 16: 1513-5.
11. Piffanelli A, Pelizzola D, Giovannini G, De Bortoli M, Catozzi L, Giganti M. Characterization of laboratory working standard for quality control of immunometric and radiometric estrogen receptor assays. Clinical evaluation on breast cancer biopsies. Italian Committee for Hormone Receptor Assays Standardization. Tumori 1989; 75: 550-6.
12. Biganzoli E, Boracchi P, Coradini D, Daidone MG, Marubini E. Prognosis in node-negative primary breast cancer: a neural network analysis of risk profiles using routinely assessed factors. Ann Oncol 2003; 14: 1484-93.
13. Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer 1990; 26: 668-70.
14. Boracchi P, Biganzoli E, Marubini E. Joint modelling of cause-specific hazard functions with cubic splines: an application to a large series of breast cancer patients. Comp Stat Data Anal 2003; 42: 243-62.
15. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of dormancy. Breast Cancer Res Treat 1996; 41: 177-85.
16. Silvestrini R, Benini E, Daidone MG, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 965-70.
17. Antolini L, Boracchi P, Biganzoli E. A time-dependent discrimination index for survival data. Stat Med 2005; 24: 3927-44.
18. Antolini L, Nam B-H, D'Agostino RB. Inference on correlated discrimination measures in survival analysis: a nonparametric approach. Communications in Statistics - Theory and Methods 2004; 33: 2117-35.
19. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
20. Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. Tenyear outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004; 22: 1630-7.
21. Collett K, Skjaerven R, Maehle BO. The prognostic contribution of estrogen and progesterone receptor status to a modified version of the Nottingham Prognostic Index. Breast Cancer Res Treat 1998; 48: 1-9.
22. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-91.
23. Bryant J, Fisher B, Gunduz N, Costantino JP, Emir B. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 1998; 51: 239-53.
24. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
25. Jansen MP, Foekens JA, van Staveren IL, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005; 23: 732-40.
26. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22: 2284-93.
27. Iwao-Koizumi K, Matoba R, Ueno N, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005; 23: 422-31.
28. Biganzoli E, Lama N, Ambrogi F, Antolini L, Boracchi P. Prediction of cancer outcome with microarrays. Lancet 2005; 365: 1683.
29. Simon R, Radmacher MD, Dobbin K. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003; 95: 14-8.
30. Biganzoli E, Boracchi P. Old and new markers for breast cancer prognosis: the need for integrated research on quantitative issues. Eur J Cancer 2004; 40: 1803-6.
31. Banerjee M, George J, Song EY, Roy A, Hryniuk W. Tree-based model for breast cancer prognostication. J Clin Oncol 2004; 22: 2567-75.
32. McCallum M, Baker C, Gillespie K, et al. A prognostic index for operable, node-negative breast cancer. Br J Cancer 2004; 90: 1933-41.
33. Feldman M, Stanford R, Catcheside A, Stotter A. The use of a prognostic table to aid decision making on adjuvant therapy for women with early breast cancer. Eur J Surg Oncol 2002; 28: 615-9.
34. Linke SP, Bremer TM, Herold CD, Sauter G, Diamond C. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin Cancer Res 2006; 12: 1175-83.
35. Lisboa PJ. A review of evidence of health benefit from artificial neural networks in medical intervention. Neural Network 2002; 15: 11-39.
36. Fitzgibbons PL, Page DL, Weaver D. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-78.